Drug Trial Radar · NCT04256317
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
316
Planned (sponsor's estimate)
Start
May 21, 2020
Primary completion
Nov 1, 2027
Study completion Nov 1, 2028
Sponsor
- Lead sponsor
- Taiho Oncology, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 5, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms, and Phase 1 and Phase 2 Combination Therapy arms. Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at escalating dose levels of oral cedazuridine and azacitidine (only one study drug will be escalated at a time) followed by a Dose Expansion Stage (Stage B). Phase 2 Monotherapy is a randomized, open-label, crossover study to compare oral ASTX030 to subcutaneous (SC) azacitidine. Phase 3 Monotherapy is a randomized open-label crossover study comparing the final fixed dose of oral ASTX030 to SC azacitidine. Phase 1 Combination Therapy is an open-label, multicenter, randomized, exploratory study comparing ASTX030 and SC azacitidine in combination with venetoclax in participants with treatment-naïve AML. Phase 2 Combination Therapy is an open-label, single arm, study evaluating the efficacy, safety, pharmacokinetics (PK), and drug interactions of ASTX030 in combination with venetoclax in participants with treatment-naïve AML. The duration of this multi-phase study is approximately 8 years.
Conditions
- Myelodysplastic Syndromes
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome/Neoplasm
- Chronic Myelomonocytic Leukemia
Interventions
AzacitidineDrug
Tablets/Capsules for oral administration and powder for reconstitution to aqueous suspension for SC administration.
ASTX030 (cedazuridine + azacitidine)Drug
FDC Capsules for oral administration.
AzacitidineDrug
Powder for reconstitution to aqueous suspension for SC administration.
ASTX030 (cedazuridine + azacitidine)Drug
Tablets/Capsules for oral administration.
CedazuridineDrug
Tablets for oral administration.
VenetoclaxDrug
Oral tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1, 2 and 3 Monotherapy: Total Cycle Area Under the Curve (AUC) From 0 to 24 Hours (AUC0-24) ExposuresTime frame: Predose and at multiple timepoints post-dose up to 24 hours
- Phase 1 Combination Therapy: Number of Participants with Treatment-emergent Adverse Events (TEAEs)Time frame: Up to 24 months
- Phase 1 and 2 Combination Therapy: Complete Response (CR) Rate as Assessed by the InvestigatorTime frame: Up to 36 months
- Phase 1 Combination Therapy: AUC0-24 of Venetoclax With ASTX030Time frame: Pre-dose and at multiple timepoints post-dose up to 24 hours on Day 7 (with ASTX030] of Cycle 1
- Phase 1 Combination Therapy: AUC0-24 of Venetoclax Without ASTX030Time frame: Pre-dose and at multiple timepoints post-dose up to 24 hours on Day 14 (without ASTX030) of Cycle 1
- Phase 1 Combination Therapy: Maximum Plasma Concentration (Cmax) of Venetoclax With ASTX030Time frame: Pre-dose and at multiple timepoints post-dose up to 24 hours on Day 7 (with ASTX030] of Cycle 1
- Phase 1 Combination Therapy: Cmax of Venetoclax Without ASTX030Time frame: Pre-dose and at multiple timepoints post-dose up to 24 hours on Day 14 (without ASTX030) of Cycle 1
Locations
73 sites in 10 countries. Site status is shown where the registry gives one.
Keck School of Medicine of USC
Los Angeles, California · Recruiting
UC Irvine Health - Chao Family Comprehensive Cancer Center
Orange, California · Recruiting
Yale University
New Haven, Connecticut · Recruiting
University of Miami - Sylvester Comprehensive Cancer Center
Miami, Florida · Recruiting
University of Emory - Winship Cancer Institute
Atlanta, Georgia · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
John Theurer Cancer Center / Hackensack University
Hackensack, New Jersey · Recruiting
Roswell Park Comprehensive Cancer Center
Buffalo, New York · Recruiting
New York University Langone Hospital - Long Island
Mineola, New York · Recruiting
Perlmutter Cancer Center - 34th Street
New York, New York · Recruiting
Icahn School of Medicine at Mount Sinai
New York, New York · Recruiting
Weill Cornell Medical Center
New York, New York · Withdrawn
Montefiore Medical Center
The Bronx, New York · Recruiting
Duke University
Durham, North Carolina · Recruiting
Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute
Columbus, Ohio · Recruiting
Oregon Health and Science University
Portland, Oregon · Recruiting
Oregon Oncology Specialists
Salem, Oregon · Recruiting
Hollings Cancer Center
Charleston, South Carolina · Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee · Recruiting
Baylor Research Institute dba Baylor Scott & White Research Institute
Dallas, Texas · Withdrawn
University of Texas Southwestern Medical Center
Dallas, Texas · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
Seattle Cancer Care Alliance
Seattle, Washington · Recruiting
Froedtert & Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
Eastern Health - Health Sciences Centre
St. John's, Newfoundland and Labrador, Canada · Recruiting
Princess Margaret Cancer Centre
Toronto, Ontario, Canada · Recruiting
Fakultni Nemocnice Ostrava
Ostrava, Moravian-Silesian, Czechia · Recruiting
Fakultní Nemocnice Královské Vinohrady
Prague, Prague, Czechia · Recruiting
Vseobecna Fakultni Nemocnice v Praze
Prague, Prague, Czechia · Recruiting
Institut Universitaire du Cancer de Toulouse (IUCT) Oncopole
Toulouse, Haute-Garonne, France · Recruiting
Hôpital Saint-Louis
Paris, Île-de-France Region, France · Recruiting
Hôpital l'Archet
Nice, Provence-Alpes-Côte d'Azur Region, France · Recruiting
Universitätsklinikum Freiburg
Freiburg im Breisgau, Baden-Wurttemberg, Germany · Recruiting
Universitätsklinikum Heidelberg
Heidelberg, Baden-Wurttemberg, Germany · Not yet recruiting
Städtisches Klinikum Braunschweig
Braunschweig, Lower Saxony, Germany · Recruiting
Universitätsklinikum Halle
Halle, Saxony-Anhalt, Germany · Recruiting
Semmelweis Egyetem Belgyógyászati és Hematológiai Klinika
Budapest, Hungary · Recruiting
Szent-Györgyi Albert Klinikai Központ, II. sz. Belgyógyászati Klinika és Kardiológiai Központ
Szeged, Csongrád megye, Hungary · Not yet recruiting
Petz Aladár Győr-Moson-Sopron Vármegyei Egyetemi Oktató Kórház
Győr, Győr-Moson-Sopron, Hungary · Recruiting
Debreceni Egyetem Klinikai Központ
Debrecen, Hajdú-Bihar, Hungary · Recruiting
Showing 40 of 73 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.